文献速递脑血管病外科神经重症

蛛网膜下腔出血患者低钠血症的预防与治疗:一项系统综述

Prevention and Treatment of Hyponatremia in Patients with Subarachnoid Hemorrhage: A Systematic Review.
PubMed 文献 · World Neurosurg · 2017-10-05

本系统综述检索 Cochrane 对照试验中心注册库、Embase、MEDLINE 和 PubMed,纳入 5 项研究(1 项前后对照观察性试验使用氟氢可的松,4 项随机对照试验中 2 项使用氟氢可的松、2 项使用氢化可的松),评估蛛网膜下腔出血患者低钠血症预防与治疗策略的疗效与安全性。所有 5 项试验至少 1 个领域存在高偏倚风险,盐皮质激素使用未统计学显著降低症状性血管痉挛发生率(相对风险 0.60,95% 置信区间 0.35-1.03,I²=0%),在 4 项随机对照试验中盐皮质激素减少尿钠排泄和容量收缩,但当前证据未显示盐皮质激素预防治疗在临床重要结局方面有获益。

要点

  • 纳入 5 项研究,所有试验至少 1 个领域存在高偏倚风险。
  • 盐皮质激素未统计学显著降低症状性血管痉挛发生率(相对风险 0.60,95% 置信区间 0.35-1.03,I²=0%)。
  • 4 项随机对照试验中盐皮质激素减少尿钠排泄和容量收缩。

核心结论

  • 当前证据未显示盐皮质激素预防治疗在临床重要结局方面有获益,但由于不精确性不能排除差异。
  • 需要更大规模、设计良好的试验来确定盐皮质激素及液体和钠补充策略对蛛网膜下腔出血患者低钠血症预防和治疗中临床相关结局的影响。

研究设计与样本

  • 系统综述,检索 Cochrane 对照试验中心注册库、Embase、MEDLINE 和 PubMed。
  • 从 117 项已识别研究中纳入 5 项:1 项前后对照观察性试验(使用氟氢可的松)和 4 项随机对照试验(2 项使用氟氢可的松,2 项使用氢化可的松)。
  • 主要结局包括神经功能结局、症状性血管痉挛等,次要结局包括钠和容量状态指标。

主要发现

  • 所有 5 项试验至少 1 个领域存在高偏倚风险。
  • 无法对功能结局进行 Meta 分析,但单项研究未显示统计学显著差异。
  • 盐皮质激素使用未统计学显著降低症状性血管痉挛发生率(相对风险 0.60,95% 置信区间 0.35-1.03,I²=0%)。
  • 研究未报告其他主要结局。
  • 在 4 项随机对照试验中,盐皮质激素使用减少尿钠排泄和容量收缩。

局限性

  • 所有 5 项试验至少 1 个领域存在高偏倚风险。
  • 无法对功能结局进行 Meta 分析。
  • 研究未报告其他主要结局。
  • 由于不精确性不能排除差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Current guidelines for the management of hyponatremia in patients with subarachnoid hemorrhage (SAH) are not based on a systematic assessment of the literature. We evaluated published studies on the efficacy and safety of current preventative and treatment strategies for hyponatremia in patients with SAH. METHODS: We searched the Cochrane Central Register of Controlled Trials, Embase, MEDLINE, and PubMed for relevant studies. Primary outcomes of interest included neurologic functional outcomes, symptomatic vasospasm, and others. Secondary outcomes included measures of sodium and volume status. RESULTS: We included 5 out of 117 identified studies: 1 before-and-after observational trial (using fludrocortisone) and 4 randomized controlled trials (2 using fludrocortisone; 2 using hydrocortisone). All 5 trials had a high risk of bias in at least 1 domain. We could not perform a meta-analysis of functional outcomes; however, individual studies did not demonstrate statistically significant differences. Mineralocorticoid use did not statistically significantly reduce the incidence of symptomatic vasospasm (relative risk, 0.60; 95% confidence interval, 0.35-1.03; I2 = 0%). The studies did not report other primary outcomes. In the 4 RCTs, mineralocorticoid use reduced natriuresis and volume contraction. CONCLUSIONS: Current evidence does not demonstrate a benefit of preventative treatment with mineralocorticoids in clinically important outcomes, although a difference cannot be ruled out due to imprecision. Larger well-designed trials are needed to establish the impact of mineralocorticoids and fluid and sodium supplementation strategies on clinically relevant outcomes in the prevention and treatment of hyponatremia in patients with SAH.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Shah K, Turgeon RD, Gooderham PA, et al. Prevention and Treatment of Hyponatremia in Patients with Subarachnoid Hemorrhage: A Systematic Review. World Neurosurg. 2017. PMID: 28987848. doi:10.1016/j.wneu.2017.09.182

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。